Local startup Seres Therapeutics is poised to be one of the first biotechs to prove bacteria can treat disease, thanks to clinical trial results released Monday.
Seres Therapeutics’ (Nasdaq: MCRB) stock price shot up more than 400% on the Monday morning news that its lead drug candidate, SER-109, succeeded in a late-stage clinical trial. The biotech will now head to the FDA for approval.
“This is a catalyst to demonstrate that the microbiome has emerged from an emerging treatment modality…
Boston Biz Journal https://www.bizjournals.com/boston/news/2020/08/10/seres-stock-jumps-400-on-microbiome-trial-success.html?ana=RSS&s=article_search